The Arming of Natural Killer Cells With Fc-Engineered Monoclonal Antibodies Confers Specificity Against Tumor B Cells

Michaël Constantinides; Loïs Coënon; Paolo Falvo; Caroline Multrier; Davide Lombardi; Francesco Bertolini; Pierre Martineau; Bruno Robert; Guillaume Cartron; Martin Villalba

doi:10.1002/mco2.70242

MedComm ›› 2025, Vol. 6 ›› Issue (7) : e70242 DOI: 10.1002/mco2.70242

LETTER

The Arming of Natural Killer Cells With Fc-Engineered Monoclonal Antibodies Confers Specificity Against Tumor B Cells

Author information +

History +

PDF

Keywords

ADCC / B-cell chronic lymphocytic leukemia / engineered mAbs / NK cell therapy / non-Hodgkin lymphoma

Cite this article

Download citation ▾

Michaël Constantinides, Loïs Coënon, Paolo Falvo, Caroline Multrier, Davide Lombardi, Francesco Bertolini, Pierre Martineau, Bruno Robert, Guillaume Cartron, Martin Villalba. The Arming of Natural Killer Cells With Fc-Engineered Monoclonal Antibodies Confers Specificity Against Tumor B Cells. MedComm, 2025, 6(7): e70242 DOI:10.1002/mco2.70242

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	G. L. Moore, H. Chen, S. Karki, and G. A. Lazar, “Engineered Fc Variant Antibodies With Enhanced Ability to Recruit Complement and Mediate Effector Functions,” MAbs 2, no. 2 (2010): 181-189.

[2]	T. Dosani, M. Carlsten, I. Maric, and O. Landgren, “The Cellular Immune System in Myelomagenesis: NK Cells and T Cells in the Development of MM and Their Uses in Immunotherapies,” Blood Cancer Journal 5, no. 4 (2015): e306-e306.

[3]	M. K. Kilgour, D. J. Bastin, S. H. Lee, M. Ardolino, S. McComb, and A. Visram, “Advancements in CAR-NK Therapy: Lessons to be Learned From CAR-T Therapy,” Frontiers in Immunology 14 (2023): 1166038.

[4]	D. Marin, Y. Li, R. Basar, et al. “Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19+ B Cell Tumors: A Phase 1/2 Trial,” Nature Medicine 30 (2024): 772-784.

[5]	L. Coënon, M. Geindreau, F. Ghiringhelli, M. Villalba, and M. Bruchard, “Natural Killer Cells at the Frontline in the Fight Against Cancer,” Cell Death & Disease 15, no. 8 (2024): 614.

[6]	L. Coënon, E. Rigal, H. Courot, et al., “Generation of Non-Genetically Modified, CAR-Like, NK Cells,” Journal for ImmunoTherapy of Cancer 12, no. 7 (2024): e009070.

[7]	D. Sanchez-Martinez, N. Allende-Vega, and S. Orecchioni, “Expansion of Allogeneic NK Cells With Efficient Antibody-Dependent Cell Cytotoxicity Against Multiple Tumors,” Theranostics 8, no. 14 (2018): 3856-3869.

[8]	A. Rossi, S. Orecchioni, P. Falvo, et al., “Dual Targeting of the DNA Damage Response Pathway and BCL-2 in Diffuse Large B-Cell Lymphoma,” Leukemia 36, no. 1 (2022): 197-209.

[9]	R. Bargou, E. Leo, G. Zugmaier, et al., “Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody,” Science 321, no. 5891 (2008): 974-977.

[10]	M. Constantinides, A. Fayd'herbe De Maudave, M. Potier-Cartereau, M. Campos-Mora, G. Cartron, and M. Villalba, “Direct Cell Death Induced by CD20 Monoclonal Antibodies on B Cell Lymphoma Cells Revealed by New Protocols of Analysis,” Cancers 15, no. 4 (2023): 1109.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.